Leerink Partners Keeps Buy Rating on Elanco Animal Health with $20 Price Target

Leerink Partners analyst Daniel Clark maintains a Buy rating on Elanco Animal Health with a price target of $20.00. The analyst consensus is a Moderate Buy with an average price target of $17.83, representing a 4.27% upside. Elanco Animal Health reported a quarterly revenue of $1.19 billion and a net profit of $67 million for the quarter ending March 31. Clark has a 75.00% success rate on recommended stocks and an average return of 18.2%.

Elanco Animal Health (ELAN) has received a series of positive analyst reports following its Q2 2025 financial results. The company reported a quarterly revenue of $1.24 billion, representing a year-over-year increase of 5%, and an adjusted EBITDA of $238 million, highlighting its operational efficiency.

Piper Sandler, an investment research firm, recently raised its price target for ELAN to $18 from $12, maintaining a Neutral rating. This move comes amidst a series of analyst forecasts and insider trading activities surrounding ELAN. For instance, Daniel Clark from Leerink Partners maintains a Buy rating on ELAN with a price target of $20.00, while Andrea Alfonso from UBS set a target price of $19.00 [1].

Elanco's Q2 2025 results reflect a company in motion. Revenue rose 5% year-over-year to $1.241 billion, with organic constant currency growth of 8%, driven by 11% growth in the U.S. Pet Health segment. The company's deleveraging strategy has reduced net leverage to 4.0x, with plans to reduce it further by year-end 2025. Additionally, ELAN's innovation pipeline is robust, with products like Credelio Quattro and Zenrelia driving growth [2].

Despite the positive analyst sentiment, ELAN's stock price has been influenced by broader market conditions and sector-specific concerns. Piper Sandler's decision to raise the price target is a reflection of the company's recent financial performance and the potential for future growth, albeit with a degree of uncertainty.

Investors should continue to monitor ELAN's stock performance and any new analyst ratings or insider trading activities for further insights into the company's prospects. With a robust pipeline, deleveraging tailwinds, and a clear path to outperforming industry benchmarks, ELAN offers investors a compelling opportunity to capitalize on a company that is redefining its category.

References:
[1] https://www.ainvest.com/news/elanco-animal-health-q2-2025-innovation-driven-growth-accelerated-deleveraging-justify-buy-rating-2508/
[2] https://www.nasdaq.com/articles/elanco-animal-health-elan-reports-q2-earnings-what-key-metrics-have-say